Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Non-Current Assets (2019 - 2025)

Harmony Biosciences Holdings' Non-Current Assets history spans 7 years, with the latest figure at $364.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 13.18% year-over-year to $364.6 million; the TTM value through Dec 2025 reached $364.6 million, down 13.18%, while the annual FY2025 figure was $364.6 million, 13.18% down from the prior year.
  • Non-Current Assets for Q4 2025 was $364.6 million at Harmony Biosciences Holdings, down from $369.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $419.9 million in Q4 2024 and bottomed at $149.0 million in Q4 2021.
  • The 5-year median for Non-Current Assets is $309.7 million (2023), against an average of $297.4 million.
  • The largest annual shift saw Non-Current Assets soared 115.38% in 2021 before it dropped 13.18% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $149.0 million in 2021, then skyrocketed by 83.61% to $273.6 million in 2022, then surged by 31.72% to $360.4 million in 2023, then grew by 16.53% to $419.9 million in 2024, then decreased by 13.18% to $364.6 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Non-Current Assets are $364.6 million (Q4 2025), $369.4 million (Q3 2025), and $416.7 million (Q2 2025).